11 results on '"Porta, M.G. Della"'
Number of results to display per page
Search Results
2. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.
- Author
-
Velden, V.H. van der, Preijers, F.W., Johansson, U., Westers, Theresia M., Dunlop, A., Porwit, A., Béné, M.C., Valent, P., Marvelde, J. Te, Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W.A., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Loken, M.R., Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Porta, M.G. Della, Burbury, K., Bellos, F., Weiß, E., Kern, W., Loosdrecht, A. van de, Velden, V.H. van der, Preijers, F.W., Johansson, U., Westers, Theresia M., Dunlop, A., Porwit, A., Béné, M.C., Valent, P., Marvelde, J. Te, Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W.A., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Loken, M.R., Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Porta, M.G. Della, Burbury, K., Bellos, F., Weiß, E., Kern, W., and Loosdrecht, A. van de
- Abstract
01 januari 2023, Item does not contain fulltext, BACKGROUND: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. METHODS: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. RESULTS: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. CONCLUSIONS: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.
- Published
- 2023
3. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group.
- Author
-
Porwit, A., Béné, M.C., Duetz, C., Matarraz, S., Oelschlaegel, U., Westers, Theresia M., Wagner-Ballon, O., Kordasti, S., Valent, P., Preijers, F.W., Alhan, C., Bellos, F., Bettelheim, P., Burbury, K., Chapuis, N., Cremers, E., Porta, M.G. Della, Dunlop, A., Eidenschink-Brodersen, L., Font, P., Fontenay, M., Hobo, W., Ireland, R., Johansson, U., Loken, M.R., Ogata, K., Orfao, A., Psarra, K., Saft, L., Subira, D., Marvelde, J. Te, Wells, D.A., Velden, V.H. van der, Kern, W., Loosdrecht, A.A. van de, Porwit, A., Béné, M.C., Duetz, C., Matarraz, S., Oelschlaegel, U., Westers, Theresia M., Wagner-Ballon, O., Kordasti, S., Valent, P., Preijers, F.W., Alhan, C., Bellos, F., Bettelheim, P., Burbury, K., Chapuis, N., Cremers, E., Porta, M.G. Della, Dunlop, A., Eidenschink-Brodersen, L., Font, P., Fontenay, M., Hobo, W., Ireland, R., Johansson, U., Loken, M.R., Ogata, K., Orfao, A., Psarra, K., Saft, L., Subira, D., Marvelde, J. Te, Wells, D.A., Velden, V.H. van der, Kern, W., and Loosdrecht, A.A. van de
- Abstract
01 januari 2023, Item does not contain fulltext, Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34(+) CD19(-) ) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.
- Published
- 2023
4. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
- Author
-
Bernard, E., Nannya, Y., Hasserjian, R.P., Devlin, S.M., Tuechler, H., Medina-Martinez, J.S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., Levine, M.F., Arango, J.E., Zhou, Y, Solé, F., Cargo, C.A., Haase, D., Creignou, M., Germing, U., Zhang, Y., Gundem, G., Sarian, A., Loosdrecht, A.A. van de, Jädersten, M., Tobiasson, M., Kosmider, O., Follo, M.Y., Thol, F., Pinheiro, R.F., Santini, V., Kotsianidis, I., Boultwood, J., Santos, F.P.S., Schanz, J., Kasahara, S., Ishikawa, T., Tsurumi, H., Takaori-Kondo, A., Kiguchi, T., Polprasert, C., Bennett, J.M., Klimek, V.M., Savona, M.R., Belickova, M., Ganster, C., Palomo, L., Sanz, G., Ades, L., Porta, M.G. Della, Smith, A.G., Werner, Y., Patel, M., Viale, A., Vanness, K., Neuberg, D.S., Stevenson, K.E., Menghrajani, K., Bolton, K.L., Fenaux, P., Pellagatti, A., Platzbecker, U., Heuser, M., Valent, P., Chiba, S., Miyazaki, Y., Finelli, C., Voso, M.T., Shih, L.Y., Fontenay, M., Jansen, J.H., Cervera, J., Atsuta, Y., Gattermann, N., Ebert, B.L., Bejar, R., Greenberg, P.L., Cazzola, M., Hellström-Lindberg, E., Ogawa, S., Papaemmanuil, E., Bernard, E., Nannya, Y., Hasserjian, R.P., Devlin, S.M., Tuechler, H., Medina-Martinez, J.S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., Levine, M.F., Arango, J.E., Zhou, Y, Solé, F., Cargo, C.A., Haase, D., Creignou, M., Germing, U., Zhang, Y., Gundem, G., Sarian, A., Loosdrecht, A.A. van de, Jädersten, M., Tobiasson, M., Kosmider, O., Follo, M.Y., Thol, F., Pinheiro, R.F., Santini, V., Kotsianidis, I., Boultwood, J., Santos, F.P.S., Schanz, J., Kasahara, S., Ishikawa, T., Tsurumi, H., Takaori-Kondo, A., Kiguchi, T., Polprasert, C., Bennett, J.M., Klimek, V.M., Savona, M.R., Belickova, M., Ganster, C., Palomo, L., Sanz, G., Ades, L., Porta, M.G. Della, Smith, A.G., Werner, Y., Patel, M., Viale, A., Vanness, K., Neuberg, D.S., Stevenson, K.E., Menghrajani, K., Bolton, K.L., Fenaux, P., Pellagatti, A., Platzbecker, U., Heuser, M., Valent, P., Chiba, S., Miyazaki, Y., Finelli, C., Voso, M.T., Shih, L.Y., Fontenay, M., Jansen, J.H., Cervera, J., Atsuta, Y., Gattermann, N., Ebert, B.L., Bejar, R., Greenberg, P.L., Cazzola, M., Hellström-Lindberg, E., Ogawa, S., and Papaemmanuil, E.
- Abstract
Contains fulltext : 229615.pdf (Publisher’s version ) (Closed access)
- Published
- 2020
5. PS1462 SECOND PRIMARY MALIGNANCIES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: REAL WORLD EVIDENCE FROM 215 CONSECUTIVELY TREATED PATIENTS IN LOMBARDY
- Author
-
Maffioli, M., primary, Giorgino, T., additional, Mora, B., additional, Iurlo, A., additional, Elli, E., additional, Finazzi, M.C., additional, Caramella, M., additional, Rumi, E., additional, Carraro, M.C., additional, Polverelli, N., additional, D’Adda, M., additional, Malato, S., additional, Rossi, M., additional, Molteni, A., additional, Vismara, A., additional, Sissa, C., additional, Spina, F., additional, Anghilieri, M., additional, Barraco, D., additional, Porta, M.G. Della, additional, and Passamonti, F., additional
- Published
- 2019
- Full Text
- View/download PDF
6. HARMONEMIA: a universal strategy for flow cytometry immunophenotyping
- Author
-
Lacombe, F., Bernal, E., Bloxham, D., Couzens, S., Porta, M.G. Della, Johansson, U., Kern, W., Macey, M., Matthes, T., Morilla, R., Paiva, A., Palacio, C., Preyers, F.W., Ratei, R., Siitonen, S., Allou, K., Porwit, A., and Béné, M.C.
- Subjects
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] - Abstract
Item does not contain fulltext
- Published
- 2016
7. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS
- Author
-
Porwit, A., Loosdrecht, A.A. van de, Bettelheim, P., Brodersen, L.E., Burbury, K., Cremers, E., Porta, M.G. Della, Ireland, R., Johansson, U., Matarraz, S., Ogata, K., Orfao, A., Preijers, F.W., Psarra, K., Subirá, D., Valent, P., Velden, V.H. van der, Wells, D., Westers, T.M., Kern, W., Béné, M.C., Porwit, A., Loosdrecht, A.A. van de, Bettelheim, P., Brodersen, L.E., Burbury, K., Cremers, E., Porta, M.G. Della, Ireland, R., Johansson, U., Matarraz, S., Ogata, K., Orfao, A., Preijers, F.W., Psarra, K., Subirá, D., Valent, P., Velden, V.H. van der, Wells, D., Westers, T.M., Kern, W., and Béné, M.C.
- Abstract
Item does not contain fulltext
- Published
- 2014
8. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
- Author
-
Malcovati, L., Hellstrom-Lindberg, E., Bowen, D., Ades, L., Cermak, J., Canizo, C. Del, Porta, M.G. Della, Fenaux, P., Gattermann, N., Germing, U., Jansen, J.H., Mittelman, M., Mufti, G., Platzbecker, U., Sanz, G.F., Selleslag, D., Skov-Holm, M., Stauder, R., Symeonidis, A., Loosdrecht, A.A. van de, Witte, T.J. de, Cazzola, M., Malcovati, L., Hellstrom-Lindberg, E., Bowen, D., Ades, L., Cermak, J., Canizo, C. Del, Porta, M.G. Della, Fenaux, P., Gattermann, N., Germing, U., Jansen, J.H., Mittelman, M., Mufti, G., Platzbecker, U., Sanz, G.F., Selleslag, D., Skov-Holm, M., Stauder, R., Symeonidis, A., Loosdrecht, A.A. van de, Witte, T.J. de, and Cazzola, M.
- Abstract
Item does not contain fulltext, Within the MDS work-package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the NIH Consensus Development Program. A systematic review of the literature was performed including indexed original papers, indexed reviews and educational papers, and abstracts of conference proceedings. Guidelines were developed based on a list of patient- and therapy-oriented questions, and recommendations were formulated and ranked according to the supporting level of evidence. MDS should be classified according to the 2008 WHO criteria. An accurate risk-assessment requires not only the evaluation of disease-related factors, but also of those related to extra-hematological comorbidity. The assessment of individual risk enables the identification of fit patients with a poor prognosis, who are candidates for up-front intensive treatments, primarily allogeneic stem cell transplantation. A high proportion of MDS patients are not eligible for potentially curative treatment because of advanced age and/or clinically relevant comorbidities and poor performance status. In these patients, the therapeutic intervention is aimed at preventing cytopenia-related morbidity and preserving quality of life. A number of new agents are being developed, for which the available evidence is not sufficient to recommend routine use. The inclusion of patients into prospective clinical trials is strongly recommended.
- Published
- 2013
9. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.
- Author
-
Westers, T.M., Ireland, R., Kern, W., Alhan, C., Balleisen, J.S., Bettelheim, P., Burbury, K., Cullen, M., Cutler, J.A., Porta, M.G. Della, Drager, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., Marvelde, J.G. Te, Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Ogata, K., Orfao, A., Porwit, A., Psarra, K., Richards, S.J., Subira, D., Tindell, V., Vallespi, T., Valent, P., Velden, V.H. van der, Witte, T.J.M. de, Wells, D.A., Zettl, F., Bene, M.C., Loosdrecht, A.A. van de, Westers, T.M., Ireland, R., Kern, W., Alhan, C., Balleisen, J.S., Bettelheim, P., Burbury, K., Cullen, M., Cutler, J.A., Porta, M.G. Della, Drager, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., Marvelde, J.G. Te, Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Ogata, K., Orfao, A., Porwit, A., Psarra, K., Richards, S.J., Subira, D., Tindell, V., Vallespi, T., Valent, P., Velden, V.H. van der, Witte, T.J.M. de, Wells, D.A., Zettl, F., Bene, M.C., and Loosdrecht, A.A. van de
- Abstract
1 juli 2012, Item does not contain fulltext, Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as 'normal', 'suggestive of', or 'diagnostic of' MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced. The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS. An ultimate goal is to refine and improve diagnosis and prognostic scoring systems. Finally, the working group stresses that FC should be part of an integrated diagnosis rather than a separate technique.
- Published
- 2012
10. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.
- Author
-
Loosdrecht, A.A. van de, Alhan, C., Bene, M.C., Porta, M.G. Della, Drager, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Homburg, C.H., Ireland, R., Jansen, J.H., Kern, W., Malcovati, L., Marvelde, J.G. Te, Mufti, G.J., Ogata, K., Orfao, A., Ossenkoppele, G.J., Porwit, A., Preijers, F.W.M.B., Richards, S.J., Schuurhuis, G.J., Subira, D., Valent, P., Velden, V.H. van der, Vyas, P., Westra, A.H., Witte, T.J.M. de, Wells, D.A., Loken, M.R., Westers, T.M., Loosdrecht, A.A. van de, Alhan, C., Bene, M.C., Porta, M.G. Della, Drager, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Homburg, C.H., Ireland, R., Jansen, J.H., Kern, W., Malcovati, L., Marvelde, J.G. Te, Mufti, G.J., Ogata, K., Orfao, A., Ossenkoppele, G.J., Porwit, A., Preijers, F.W.M.B., Richards, S.J., Schuurhuis, G.J., Subira, D., Valent, P., Velden, V.H. van der, Vyas, P., Westra, A.H., Witte, T.J.M. de, Wells, D.A., Loken, M.R., and Westers, T.M.
- Abstract
Contains fulltext : 81483.pdf (publisher's version ) (Open Access), The myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more cell lineages and increased risk of evolution to acute myeloid leukemia (AML). Recent advances in immunophenotyping of hematopoietic progenitor and maturing cells in dysplastic bone marrow point to a useful role for multiparameter flow cytometry (FCM) in the diagnosis and prognostication of myelodysplastic syndromes. In March 2008, representatives from 18 European institutes participated in a European LeukemiaNet (ELN) workshop held in Amsterdam as a first step towards standardization of FCM in myelodysplastic syndromes. Consensus was reached regarding standard methods for cell sampling, handling and processing. The group also defined minimal combinations of antibodies to analyze aberrant immunophenotypes and thus dysplasia. Examples are altered numbers of CD34(+) precursors, aberrant expression of markers on myeloblasts, maturing myeloid cells, monocytes or erythroid precursors and the expression of lineage infidelity markers. When applied in practice, aberrant FCM patterns correlate well with morphology, the subclassification of myelodysplastic syndromes, and prognostic scoring systems. However, the group also concluded that despite strong evidence for an impact of FCM in myelodysplastic syndromes, further (prospective) validation of markers and immunophenotypic patterns are required against control patient groups as well as further standardization in multi-center studies. Standardization of FCM in myelodysplastic syndromes may thus contribute to improved diagnosis and prognostication of myelodysplastic syndromes in the future.
- Published
- 2009
11. IN5 What's new in myelodysplastic syndromes?
- Author
-
Porta, M.G. Della, primary
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.